Impact of host genomic variation on clinical outcomes in HIV patients

Leading partner organisation: REGION HOVEDSTADEN/Centre of Excellence for Health, Immunity and Infections (CHIP) (Denmark)

The HIV epidemiology and virology related tasks will be complemented by clinically oriented activities based on host genetics.

CARE aims at performing an assessment of the treatment-limiting toxicity for existing antiretroviral drugs through:

  • Establishment of a pilot cohort for the study of the impact of host genetics on the risk of development of AIDS and serious non-AIDS events, and adverse drug reactions in HIV-positive patients in Eastern Europe (Russia, Georgia and Ukraine), based on the single nucleotide polymorphism study performed at CHIP/RegionH

  • Preliminary validation of the data by comparing it to an existing extensive cohort in relation to most common treatment regimens

Heading 1

Heading 1

Heading 1

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825673.

Subscribe to the CARE newsletter

Francesca Incardona